Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 34, Issue 1, 2010, Pages 193-203

  Gibrat, C ^a   Bousquet, M ^a   Saint Pierre, M ^a   Levesque D ^b   Calon, F ^a,c   Rouillard, C ^a,c   Cicchetti, F ^a,c  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITÉ LAVAL   (Canada)

Author keywords

mRNA; Neuroprotection; Neurotrophin; Parkinson's disease; Tyrosine hydroxylase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CYSTAMINE; HEAT SHOCK PROTEIN 70; MESSENGER RNA; NUCLEAR RECEPTOR RELATED FACTOR 1; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG MECHANISM; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; MALE; MOUSE; NERVE FIBER C; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; SINGLE DRUG DOSE; SUBSTANTIA NIGRA; TREATMENT DURATION; UPREGULATION;

ANALYSIS OF VARIANCE; ANIMALS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELL COUNT; CYSTAMINE; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HSP70 HEAT-SHOCK PROTEINS; MALE; MICE; MICE, INBRED C57BL; MPTP POISONING; RECEPTOR, TRKB; RNA, MESSENGER; TIME FACTORS; TYROSINE 3-MONOOXYGENASE; UP-REGULATION;

EID: 73849102868     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.11.005     Document Type: Article

References (37)

1. Allen P. Allen brain atlas (2008), Allen Institute for Brain Science, Seattle (WA). http://www.brain-map.org Available from: http://www.brain-map.org
2. Baquet Z.C., Bickford P.C., and Jones K.R. Brain-derived neurotrophic factor is required for the establishment of the proper number of dopaminergic neurons in the substantia nigra pars compacta. J Neurosci 25 (2005) 6251-6259
3. Beaudry G., Langlois M.C., Weppe I., Rouillard C., and Levesque D. Contrasting patterns and cellular specificity of transcriptional regulation of the nuclear receptor nerve growth factor-inducible B by haloperidol and clozapine in the rat forebrain. J Neurochem 75 (2000) 1694-1702
4. Boris-Moller F., Kamme F., and Wieloch T. The effect of hypothermia on the expression of neurotrophin mRNA in the hippocampus following transient cerebral ischemia in the rat. Brain Res Mol Brain Res 63 (1998) 163-173
5. Borrell-Pages M., Canals J.M., Cordelieres F.P., Parker J.A., Pineda J.R., Grange G., et al. Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest 116 (2006) 1410-1424
6. Bousquet M., Saint-Pierre M., Julien C., Salem Jr. N., Cicchetti F., and Calon F. Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. Faseb J 22 (2008) 1213-1225
7. Cossette M., Parent A., and Levesque D. Tyrosine hydroxylase-positive neurons intrinsic to the human striatum express the transcription factor Nurr1. Eur J NeuroSci 20 (2004) 2089-2095
8. D'Cruz B.J., Fertig K.C., Filiano A.J., Hicks S.D., DeFranco D.B., and Callaway C.W. Hypothermic reperfusion after cardiac arrest augments brain-derived neurotrophic factor activation. J Cereb Blood Flow Metab 22 (2002) 843-851
9. Dedeoglu A., Kubilus J.K., Jeitner T.M., Matson S.A., Bogdanov M., Kowall N.W., et al. Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 22 (2002) 8942-8950
10. Dong Z., Wolfer D.P., Lipp H.P., and Bueler H. Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease. Molec Ther 11 (2005) 80-88
11. Dubinsky R., and Gray C. CYTE-I-HD: phase I dose finding and tolerability study of cysteamine (Cystagon) in Huntington's disease. Mov Disord 21 (2006) 530-533
12. Fumagalli F., Racagni G., and Riva M.A. Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease. Pharmacogenomics J 6 (2006) 95-104
13. Galpern W.R., Frim D.M., Tatter S.B., Altar C.A., Beal M.F., and Isacson O. Cell-mediated delivery of brain-derived neurotrophic factor enhances dopamine levels in an MPP+ rat model of substantia nigra degeneration. Cell Transplant 5 (1996) 225-232
14. Gibrat C., Tremblay M., Saint-Pierre M., Levesque D., Rouillard C., and Cicchetti F. Neuroprotective properties of cystamine in acute vs chronic models of Parkinson. Can Assoc Neurosci 34 supplement 3 (2007) S42
15. Gibrat C., Saint-Pierre M., Bousquet M., Levesque D., Rouillard C., and Cicchetti F. Differences between subacute and chronic MPTP mice models: investigation of dopaminergic neuronal degeneration and alpha-synuclein inclusions. J Neurochem 109 (2009) 1469-1482
16. Glaser J.R., and Glaser E.M. Stereology, morphometry, and mapping: the whole is greater than the sum of its parts. J Chem Neuroanat 20 (2000) 115-126
17. Hsu T.C., Chen Y.C., Lai W.X., Chiang S.Y., Huang C.Y., and Tzang B.S. Beneficial effects of treatment with cystamine on brain in NZB/W F1 mice. Eur J Pharmacol 591 (2008) 307-314
18. Huang E.J., and Reichardt L.F. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci 24 (2001) 677-736
19. Karpuj M.V., Becher M.W., Springer J.E., Chabas D., Youssef S., Pedotti R., et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 8 (2002) 143-149
20. Lapointe N., St-Hilaire M., Martinoli M.G., Blanchet J., Gould P., Rouillard C., et al. Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J 18 (2004) 717-719
21. Lein E.S., Hawrylycz M.J., et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 445 (2007) 168-176
22. Levin E.D., Addy N., Baruah A., Elias A., Christopher N.C., Seidler F.J., et al. Prenatal chlorpyrifos exposure in rats causes persistent behavioral alterations. Neurotoxicol Teratol 24 (2002) 733-741
23. Lu B., Pang P.T., and Woo N.H. The yin and yang of neurotrophin action. Nat Rev Neurosci 6 (2005) 603-614
24. Nass R., and Przedborski S. Parkinson's disease: molecular and therapeutic insights from model systems (2008), Academic Press Inc. 978-0-12-374028-1
25. Pillai A., Veeranan-Karmegam R., Dhandapani K.M., and Mahadik S.P. Cystamine prevents haloperidol-induced decrease of BDNF/TrkB signaling in mouse frontal cortex. J Neurochem 107 (2008) 941-951
26. Rokutan K., Hirakawa T., Teshima S., Nakano Y., Miyoshi M., Kawai T., et al. Implications of heat shock/stress proteins for medicine and disease. J Med Investig 44 (1998) 137-147
27. Seroogy K.B., Lundgren K.H., Tran T.M., Guthrie K.M., Isackson P.J., and Gall C.M. Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs. J Comp Neurol 342 (1994) 321-334
28. Shieh C.H., Hong C.J., Huang Y.H., and Tsai S.J. Potential antidepressant properties of cysteamine on hippocampal BDNF levels and behavioral despair in mice. Prog Neuropsychopharmacol Biol Psychiatry 32 (2008) 1590-1594
29. Sofroniew M.V., Howe C.L., and Mobley W.C. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 24 (2001) 1217-1281
30. Stack E.C., Ferro J.L., Kim J., Del Signore S.J., Goodrich S., Matson S., et al. Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease. Biochim Biophys Acta 1782 (2008) 151-162
31. Swerdlow N.R., Keith V.A., Braff D.L., and Geyer M.A. Effects of spiperone, raclopride, SCH 23390 and clozapine on apomorphine inhibition of sensorimotor gating of the startle response in the rat. J Pharmacol Exp Ther 256 (1991) 530-536
32. Timofeeva O.A., Sanders D., Seemann K., Yang L., Hermanson D., Regenbogen S., et al. Persistent behavioral alterations in rats neonatally exposed to low doses of the organophosphate pesticide, parathion. Brain Res Bull 77 (2008) 404-411
33. Tremblay M.E., Saint-Pierre M., Bourhis E., Levesque D., Rouillard C., and Cicchetti F. Neuroprotective effects of cystamine in aged parkinsonian mice. Neurobiol Aging 27 (2006) 862-870
34. Volpicelli F., Caiazzo M., Greco D., Consales C., Leone L., Perrone-Capano C., et al. BDNF gene is a downstream target of Nurr1 transcription factor in rat midbrain neurons in vitro. J Neurochem 102 (2007) 441-453
35. vom Saal F.S., Timms B.G., Montano M.M., Palanza P., Thayer K.A., Nagel S.C., et al. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc Natl Acad Sci U S A 94 (1997) 2056-2061
36. von Bohlen und Halbach O., Minichiello L., and Unsicker K. Haploinsufficiency for trkB and trkC receptors induces cell loss and accumulation of alpha-synuclein in the substantia nigra. FASEB J 19 (2005) 1740-1742
37. Zetterstrom R.H., Solomin L., Jansson L., Hoffer B.J., Olson L., and Perlmann T. Dopamine neuron agenesis in Nurr1-deficient mice. Science 276 (1997) 248-250